Previous 10 | Next 10 |
2024-01-21 09:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. U.S. equities rose in ...
2024-01-19 14:33:49 ET Summary BioMarin Pharmaceutical is a biotech company that focuses on delivering enzyme products for rare genetic disorders. The company has launched two new products, Voxzogo for Achondroplasia and Valoctocogene Roxaparvovec (Roctavian) for severe hemophilia...
2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...
2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA PR Newswire SAN RAFAEL, Calif. , Jan. 3, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announ...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
2023-12-21 11:45:02 ET RBC Capital analyst issues SECTOR PERFORM recommendation for BMRN on December 21, 2023 12:00PM ET. The previous analyst recommendation was Sector Perform. BMRN was trading at $94.52 at issue of the analyst recommendation. The overall analyst consen...
2023-12-21 11:11:55 ET More on BioMarin Pharmaceutical BioMarin: Keeping Bullish View After Q3 Earnings BioMarin Pharmaceutical Inc. 2023 Q3 - Results - Earnings Call Presentation Biomarin Pharmaceutical, Inc. (BMRN) Q3 2023 Earnings Call Transcript BioMarin ...
2023-12-20 17:01:11 ET BioMarin ( NASDAQ: BMRN ) said that it has established a strategic review committee, temporarily expanded its board and entered into a cooperation agreement with key investor Elliott Investment Management. The biotech company said the new Strategic and Ope...
2023-12-15 12:11:32 ET More on BioMarin Pharmaceutical BioMarin: Keeping Bullish View After Q3 Earnings BioMarin Pharmaceutical 2023 Q3 - Results - Earnings Call Presentation Biomarin Pharmaceutical Q3 2023 Earnings Call Transcript BioMarin Pharmaceutical off...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
2024-05-13 17:00:06 ET Cory Kasimov from Evercore ISI issued a price target of $113.00 for BMRN on 2024-05-13 16:10:00. The adjusted price target was set to $113.00. At the time of the announcement, BMRN was trading at $80.5. The overall price target consensus is at $114...
2024-05-09 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV PR Newswire SAN RAFAEL, Calif. , May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that ...